Original Research
This study was designed to evaluate the antiplatelet effect of deferiprone in patients with transfusion-dependent β-thalassaemia/Hb E at the dose of iron-chelation therapy. The results may provide a mechanistic insight in antiplatelet effects and support the benefit of deferiprone in the prevention of thrombotic events in β-thalassaemia.
Review
This review provides an overview of the currently available iron chelator formulations, with a focus on a comparison between deferasirox DT for oral suspension and deferasirox FCT. The new formulation may be associated with fewer side effects and has increased bioavailability. In addition, alternative strategies for iron chelation, such as combining two different iron chelators, will be discussed.
